What Is Going On With HealthEquity (HQY)?

Executive shake-up at HealthEquity

HealthEquity (HQY) investors just saw a leadership change. The company ended Chief Commercial Officer Michael Fiore’s employment without cause on October 5, 2026, and distributed his responsibilities across the existing management team.

HealthEquity’s recent decision to remove its Chief Commercial Officer comes after a softer patch for the shares, with the 30 day share price return down 3.27% and the 90 day share price return down 6.93%. At the same time, the 3 year total shareholder return of 25.88% and 5 year total shareholder return of 36.16% still point to a stronger longer term record and indicate that recent momentum has faded rather than reset the broader story.

Contrast HealthEquity’s leadership reshuffle with other healthcare platforms by scanning a hand-picked 33 healthcare AI stocks that could see sentiment swing just as sharply on executive or product news.

After a leadership exit and a share price that has cooled over 1 year yet still sits on solid multi year returns, does HealthEquity now offer a favourable risk reward, or is the recent dip too small to matter?

Most Popular Narrative: 23% Undervalued

HealthEquity’s most followed valuation story pegs fair value at $119.33, well above the recent $92.03 close. This puts this leadership change against a backdrop of a stock that narrative followers still see as trading at a discount.

HealthEquity is progressing its shift from a pure HSA administrator toward an integrated healthcare financial operating system, with growing mobile engagement such as 1.4 million monthly active app users. This can deepen member activity and support higher fee and interchange revenue per account.

See why 5 investors see HealthEquity as 23% undervalued.

Result: Fair Value of $119.33 (UNDERVALUED)

Still, the HealthEquity story can crack if employment softens and new employer HSA sign ups slow, or if ongoing fee pressure keeps service revenue growth muted.

Find out about the key risks to this HealthEquity narrative.

Another view on HealthEquity’s valuation

The story around HealthEquity looks different once you zoom in on the P/E. The stock trades at 32.2x earnings, compared with 24.9x for the wider US Healthcare group and 31.5x for peers, while the fair ratio is 25.8x on Simply Wall St’s model. That gap points to a richer tag that could compress if sentiment cools, so how comfortable are you paying a premium multiple on top of an already optimistic narrative?

To see how this price tag squares with the earnings profile and where that fair ratio might matter most, take a closer look at the valuation breakdown through See what the numbers say about this price — find out in our valuation breakdown..

For a visual read on how HealthEquity’s earnings multiple stacks up against its sector, check the latest comparison in

.

Next Steps

Reading this, you might feel the HealthEquity story could break either way, so move quickly and test the thesis against your own expectations. To see which potential upside factors our data highlights, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond HealthEquity?

If the HealthEquity story has you thinking harder about risk, return and timing, do not stop here. Broaden your watchlist now or the better opportunities pass straight by.

• Target stability first by reviewing a 32 resilient stocks with low risk scores that focuses on businesses with resilient profiles when conditions turn choppy.
• Hunt for value by scanning a 33 high quality undervalued stocks that blends strong fundamentals with prices that sit below estimated worth.
• Spot future leaders early by checking a 20 high quality undiscovered gems that highlights quality companies still off most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com